Aclaris Therapeutics, Inc. (ACRS) on GreekSoup https://greeksoup.ai/stocks/us/acrs/ Every dated entry in the public record on Aclaris Therapeutics, Inc.: results, filings, insider trades and the rest, from the filings, the last 90 days. en Fri, 30 Oct 2026 00:00:00 +0000 Aclaris Therapeutics, Inc. filed 8-K: material agreementhttps://greeksoup.ai/stocks/us/acrs/filings/us:ACRS:filing:2026-10-27:6a05cff90cTue, 27 Oct 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]> Aclaris Therapeutics, Inc. filed 8-K: results of operations, regulation fd disclosure, other eventshttps://greeksoup.ai/stocks/us/acrs/filings/us:ACRS:filing:2026-10-27:6394c354eeTue, 27 Oct 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]> Aclaris Therapeutics, Inc.: short interest 15,027,284 shares at the 15 October 2026 settlement, 2.95 days to coverhttps://greeksoup.ai/stocks/us/acrs/short-interest/us:ACRS:short-interest:2026-10-15:4e65dfb7e1Thu, 15 Oct 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> Aclaris Therapeutics, Inc.: short interest 18,191,280 shares at the 30 September 2026 settlement, 6.48 days to coverhttps://greeksoup.ai/stocks/us/acrs/short-interest/us:ACRS:short-interest:2026-09-30:76a3063f55Wed, 30 Sep 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> Aclaris Therapeutics, Inc.: Schedule 13G filed by Frazier Life Sciences Public Fund, L.P., 5.4% of the classhttps://greeksoup.ai/stocks/us/acrs/holders/us:ACRS:schedule-13:2026-09-21:5ce5b66c8dMon, 21 Sep 2026 00:00:00 +0000Schedule 13D/13GSchedule 13D/13G. The filing. The page on GreekSoup.

]]> Aclaris Therapeutics, Inc.: short interest 16,075,295 shares at the 15 September 2026 settlement, 6.38 days to coverhttps://greeksoup.ai/stocks/us/acrs/short-interest/us:ACRS:short-interest:2026-09-15:6720e7c481Tue, 15 Sep 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> Aclaris Therapeutics, Inc.: short interest 15,180,778 shares at the 31 August 2026 settlement, 8.67 days to coverhttps://greeksoup.ai/stocks/us/acrs/short-interest/us:ACRS:short-interest:2026-08-31:baf5eb7dc5Mon, 31 Aug 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> Aclaris Therapeutics, Inc.: Schedule 13G/A filed by RA Capital Management, L.P., 9.1% of the classhttps://greeksoup.ai/stocks/us/acrs/holders/us:ACRS:schedule-13:2026-08-14:050ac8aba4Fri, 14 Aug 2026 00:00:00 +0000Schedule 13D/13GSchedule 13D/13G. The filing. The page on GreekSoup.

]]> Aclaris Therapeutics, Inc.: short interest 14,710,712 shares at the 14 August 2026 settlement, 7.01 days to coverhttps://greeksoup.ai/stocks/us/acrs/short-interest/us:ACRS:short-interest:2026-08-14:85b65ae7b4Fri, 14 Aug 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> Aclaris Therapeutics, Inc. Q2 FY2026 results: revenue $2 million, net income -$22 millionhttps://greeksoup.ai/stocks/us/acrs/results/fy2026-q2/us:ACRS:result:2026-08-06:28d31a1120Thu, 06 Aug 2026 00:00:00 +0000ResultsResults. The filing. The page on GreekSoup.

]]> Aclaris Therapeutics, Inc. filed 8-K: material agreementhttps://greeksoup.ai/stocks/us/acrs/filings/us:ACRS:filing:2026-08-06:45c6e917b2Thu, 06 Aug 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]> Aclaris Therapeutics, Inc. filed S-3ASR: s-3asrhttps://greeksoup.ai/stocks/us/acrs/filings/us:ACRS:filing:2026-08-06:53eec3dcafThu, 06 Aug 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]> Aclaris Therapeutics, Inc. filed 10-Q: 10-qhttps://greeksoup.ai/stocks/us/acrs/filings/us:ACRS:filing:2026-08-06:3c69f2a1d4Thu, 06 Aug 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]> Aclaris Therapeutics, Inc. filed 8-K: results of operationshttps://greeksoup.ai/stocks/us/acrs/filings/us:ACRS:filing:2026-08-06:bfabb9c068Thu, 06 Aug 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]>